Global GLP Analogs Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global GLP Analogs Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Glucagon like peptide-1 (GLP-1) agonists is the agonists of the GLP-1 receptor. This class of drugs is used for the treatment of type 2 diabetes. One of their advantages is over older insulin secretagogues, such as sulfonylureas or meglitinides, and they have a lower risk of causing hypoglycemia.
GLP Analogs report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global GLP Analogs market is projected to reach US$ 7350.9 million in 2029, increasing from US$ 5387 million in 2022, with the CAGR of 4.3% during the period of 2024 to 2029. Demand from Hospital and Pharmacy are the major drivers for the industry.
The Glucagon-like peptide 1 (GLP-1) market is driven by the increasing prevalence of diabetes and the growing demand for effective and innovative diabetes treatments. GLP-1 is a hormone that plays a crucial role in regulating blood sugar levels and is used in the treatment of type 2 diabetes. The rise in the number of diabetic patients and the need for better glycemic control contribute to market growth as GLP-1-based therapies offer significant benefits, including glucose-lowering effects and weight management. Moreover, advancements in GLP-1 analog formulations, such as long-acting and once-weekly options, have improved patient compliance and treatment outcomes. However, the market also faces challenges, including the cost of GLP-1 treatments and the need for further research to optimize dosing and combination therapies. Additionally, addressing the barriers to GLP-1 adoption, such as injection-related fears, can pose obstacles for broader market penetration. To succeed, companies must focus on research and development to offer innovative and cost-effective GLP-1 therapies, collaborate with healthcare providers to optimize treatment regimens, and address the challenges to meet the increasing demand for effective and well-tolerated diabetes treatments based on GLP-1.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global GLP Analogs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Novo Nordisk
AstraZeneca
Eli Lily
GSK
Sanofi
Bristol-Myers Squibb
Amylin
Segment by Type
Exenatied
Liraglutide
Lixisenatide
Albiglutide
Dulaglutide
Hospital
Pharmacy
Other
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the GLP Analogs market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of GLP Analogs, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the GLP Analogs industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of GLP Analogs in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, GLP Analogs introduction, etc. GLP Analogs Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of GLP Analogs market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
GLP Analogs report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global GLP Analogs market is projected to reach US$ 7350.9 million in 2029, increasing from US$ 5387 million in 2022, with the CAGR of 4.3% during the period of 2024 to 2029. Demand from Hospital and Pharmacy are the major drivers for the industry.
The Glucagon-like peptide 1 (GLP-1) market is driven by the increasing prevalence of diabetes and the growing demand for effective and innovative diabetes treatments. GLP-1 is a hormone that plays a crucial role in regulating blood sugar levels and is used in the treatment of type 2 diabetes. The rise in the number of diabetic patients and the need for better glycemic control contribute to market growth as GLP-1-based therapies offer significant benefits, including glucose-lowering effects and weight management. Moreover, advancements in GLP-1 analog formulations, such as long-acting and once-weekly options, have improved patient compliance and treatment outcomes. However, the market also faces challenges, including the cost of GLP-1 treatments and the need for further research to optimize dosing and combination therapies. Additionally, addressing the barriers to GLP-1 adoption, such as injection-related fears, can pose obstacles for broader market penetration. To succeed, companies must focus on research and development to offer innovative and cost-effective GLP-1 therapies, collaborate with healthcare providers to optimize treatment regimens, and address the challenges to meet the increasing demand for effective and well-tolerated diabetes treatments based on GLP-1.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global GLP Analogs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Novo Nordisk
AstraZeneca
Eli Lily
GSK
Sanofi
Bristol-Myers Squibb
Amylin
Segment by Type
Exenatied
Liraglutide
Lixisenatide
Albiglutide
Dulaglutide
Segment by Application
Hospital
Pharmacy
Other
Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the GLP Analogs market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of GLP Analogs, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the GLP Analogs industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of GLP Analogs in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, GLP Analogs introduction, etc. GLP Analogs Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of GLP Analogs market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices